At the news
? BULLISHIMPACT 6/10 8-K filed Sep 9, 2026 at 07:10 ET
Tyra Biosciences announced positive initial Phase 2 data for oral dabogratinib in FGFR3-altered low-grade intermediate-risk NMIBC, showing 79% ORR and 64% complete response rate at 60 mg QD with favorable safety (no Grade 4/5 AEs, no dose reductions). The company plans to initiate a registrational adjuvant study in 2027, targeting a >$5B market opportunity.
- SURF302 Phase 2 ORR 79% (11/14) at 60 mg QD at 3-month and best overall response; CR 64% (9/14) BOR
- No Grade 4 or 5 treatment-emergent adverse events; Grade 3 TEAEs in 14% at 60 mg; none at 60 mg were treatment-related
- Plans to complete 60 mg enrollment, initiate 70 mg cohort, engage health authorities on Phase 3 design, and start registrational adjuvant study in 2027
- SURF303 first LG UTUC patient achieved CR at 3 months with no TEAEs; BEACH301 cleared fifth dose level in achondroplasia cohort
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access